State Street’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

State Street’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-10,201	Closed	-$39K	–	3842
2019 Q3	$39K	Hold	10,201	–	–	﹤0.01%	3734
2019 Q2	$68K	Sell	10,201 -97,628	-91%	-$372K	﹤0.01%	3702
2019 Q1	$383K	Buy	107,829 +15,778	+17%	+$85.6K	﹤0.01%	3480
2018 Q4	$365K	Buy	92,051 +21,354	+30%	+$273K	﹤0.01%	3490
2018 Q3	$1.4M	Buy	70,697 +28,201	+66%	+$713K	﹤0.01%	3348
2018 Q2	$1.35M	Buy	42,496 +3,962	+10%	+$143K	﹤0.01%	3362
2018 Q1	$1.43M	Buy	38,534 +6,237	+19%	+$410K	﹤0.01%	3277
2017 Q4	$2.55M	Buy	+32,297	New	+$2.39M	﹤0.01%	3093

Other funds holding MLNT

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CCM

Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

State Street's MLNT Position: Q4 2019 in Review

State Street sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q4 2019, closing a stake of 10,201 shares — an estimated $39K sold.

State Street first reported a position in MLNT in Q4 2017 and held it in 8 quarters. The position peaked at $2.55M in Q4 2017. 37 funds tracked by Wall St. Rank hold MLNT as of Q4 2019.

State Street reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
State Street sold 10,201 Melinta Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $39K.
State Street first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 8 quarters.
State Street's Melinta Therapeutics, Inc. Common Stock position peaked at $2.55M in Q4 2017.
37 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q4 2019.

Based on State Street's 13F filing for Q4 2019, filed 6 Feb 2020.